Literature DB >> 11679156

HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression.

N Ngo-Giang-Huong1, D Candotti, A Goubar, B Autran, M Maynart, D Sicard, J P Clauvel, H Agut, D Costagliola, C Rouzioux.   

Abstract

The helper T type 1 (Th1) function of CD4(+) T lymphocytes is presumed to be of key importance in host defense against HIV-1. As the production of different antibody isotypes is dependent on this helper T function, we investigated whether HIV-1-specific responses of a particular IgG isotype could be a reliable marker of long-term HIV-1 control. Assessment of the IgG subclass distribution in the plasma of HIV-1-infected patients enrolled in the French prospective Asymptomatic Long-Term (ALT) cohort showed that IgG2 directed against HIV-1 Env gp41 and Gag proteins was associated with low viral load, high CD4(+) lymphocyte count, and weak neutralizing activity. By contrast, levels of anti-Env and anti-Pol IgG1 as well as the magnitude of neutralizing activity were correlated with the viral load and thus merely reflect the level of HIV replication. Furthermore, IgG2 directed against Gag proteins was significantly associated with HIV-1 p24-specific Th1 cell production of interferon gamma and interleukin 2. In multivariate analysis, only two variables, anti-gp41 IgG2 and plasma HIV-1 RNA, were found to be independent prognostic factors of remaining long-term nonprogressive over time. By providing new insight into the nature of an HIV-specific antibody response associated with the control of virus replication, these findings have implications for the design of HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679156     DOI: 10.1089/088922201753197105

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  29 in total

1.  HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.

Authors:  S Resino; I Galán; A Pérez; J A León; E Seoane; D Gurbindo; M Angeles Muñoz-Fernandez
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

2.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 3.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

4.  Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Elizabeth G McAndrew; Stephen Tsoukas; Anna F Licht; Darrell J Irvine; Galit Alter
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

Review 5.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

6.  Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.

Authors:  Roberto Bellucci; Sabine Oertelt; Meagan Gallagher; Sigui Li; Emmanuel Zorn; Edie Weller; Fabrice Porcheray; Edwin P Alyea; Robert J Soiffer; Nikhil C Munshi; M Eric Gershwin; Jerome Ritz
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

7.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

8.  Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.

Authors:  Ebony Gary; Margaret O'Connor; Marita Chakhtoura; Virginie Tardif; Ogan K Kumova; Delphine C Malherbe; William F Sutton; Nancy L Haigwood; Michele A Kutzler; Elias K Haddad
Journal:  Vaccine       Date:  2020-04-10       Impact factor: 3.641

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 10.  HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.